COLLABORATION, LICENSE AND DEVELOPMENT AGREEMENT BETWEEN ISIS PHARMACEUTICALS, INC., AND ASTRAZENECA ABCollaboration, License and Development Agreement • February 28th, 2013 • Isis Pharmaceuticals Inc • Pharmaceutical preparations • New York
This COLLABORATION, LICENSE AND DEVELOPMENT AGREEMENT (the “Agreement”) is entered into as of the 7th day of December, 2012 (the “Effective Date”) by and between ISIS PHARMACEUTICALS, INC., a Delaware corporation, having its principal place of business at 2855 Gazelle Court, Carlsbad, CA 92010 (“Isis”), and ASTRAZENECA AB, a company incorporated in Sweden under no. 556011-7482 with offices at SE-151 85 Södertälje, Sweden (“AstraZeneca”). AstraZeneca and Isis each may be referred to herein individually as a “Party” or collectively as the “Parties.” Capitalized terms used in this Agreement, whether used in the singular or the plural, have the meaning set forth in APPENDIX 1. All attached appendices and schedules are a part of this Agreement.
